In a regulatory filing, Immunome (IMNM) disclosed that its CEO Clay Siegall bought 137.1K shares of common stock on March 26th in a total transaction size of $999.5K. Shares are up 7.2% at $7.60 in pre-market trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement
- Immunome CTO buys $103.6K in common stock
- Immunome’s Promising Pipeline and Strategic Acquisition Drive Buy Rating
- Immunome’s Promising Pipeline and Strategic Advancements Support Buy Rating
- Immunome’s 2024 Financial Results and Pipeline Progress